Lung Cancer Adoptive Cell Therapy: Inspiring TIL ACT Comes Center Stage

Cancer Discov. 2024 Aug 2;14(8):1366-1368. doi: 10.1158/2159-8290.CD-24-0645.

Abstract

Schoenfeld and colleagues report, in this issue, a measurable objective response rate in 6/28 (21.4%) of patients with advanced non-small cell lung cancer treated with lifileucel, a cell therapy product based on autologous tumor-infiltrating lymphocytes (TIL). Extending solid evidence in advanced melanoma that led to FDA approval of lifileucel, this new evidence bodes well for treating patients with other common tumor histologies, justifying important efforts by a large number of academic and biotechnology companies engaged in improving the TIL process. See related article by Schoenfeld et al., p. 1389 (1).

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / immunology
  • Carcinoma, Non-Small-Cell Lung* / therapy
  • Humans
  • Immunotherapy, Adoptive* / methods
  • Lung Neoplasms* / therapy
  • Lymphocytes, Tumor-Infiltrating* / immunology
  • Lymphocytes, Tumor-Infiltrating* / transplantation